All In Biotech

NDA 218590 · Knoa Pharma

Zurnai (Autoinjector)

Nalmefene Hydrochloride · Intramuscular, Subcutaneous

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Aug 7, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

37

9 Phase 3, 2 recruiting

FAERS reports

32

29 serious, 6 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 31, 2026.

ZURNAI is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZURNAI is not a substitute for emergency medical care. ZURNAI is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. ( 1 ) ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) ZURNAI is not a substitute for emergency medical care. ( 1 )

Mechanism: ZURNAI is an antagonist at opioid receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 7, 2024 Original approval · Type 3 - New Dosage Form · priority review LetterLabelReview
1 products under this application
  • ZURNAI (AUTOINJECTOR) · NALMEFENE HYDROCHLORIDE EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML) · SOLUTION, INTRAMUSCULAR, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nalmefene" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • coma5
  • bradycardia4
  • bradypnoea4
  • electrocardiogram qt prolonged4
  • hypothermia4
  • intentional overdose4
  • miosis4
  • diabetic ketoacidosis3
  • pneumonia aspiration3
  • pulmonary oedema3
  • sudden death3
  • bipolar i disorder2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20053
20103
20131
20143
20151
20171
20185
20221
20232
20243
20254
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 131 on PubMed

Sponsor: Knoa Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.